此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Retrospective Continuous Glucose Monitor (CGM) Study on Glycemic Response and Body Composition in College Students (RCSOGRABCICS)

2026年9月8日 更新者:He Eye Hospital

A Retrospective Study of Individual Glycemic Response Based on CGM Wearable Devices in Weight and Body Composition Management Among College Students

This retrospective study evaluates the real-world effect of individualized glycemic response-guided dietary management, based on continuous glucose monitoring (CGM), on weight and body composition in overweight and obese university students. All data for this analysis were retrospectively retrieved from the archived records of a randomized controlled trial conducted at He University, in which 60 students (body mass index [BMI] ≥ 24 kg/m² or elevated body fat percentage) had worn CGM sensors for 4 weeks. The archived records show that the exposed group (n = 30) had received individualized dietary guidance generated from their own glucose responses, including structured CGM reports, meal composition and eating-order advice, and standardized feedback, whereas the non-exposed group (n = 30) had worn CGM without receiving any dietary guidance. One non-exposed participant was excluded from this retrospective analysis for missing primary outcome data, leaving 59 participants for analysis. The archived dataset contains body composition (weight, body mass index [BMI], body fat mass, percent body fat, skeletal muscle mass, visceral fat level) and eating behavior records at Day 0, Day 28, and Day 90. This analysis examines whether the 4-week intervention produced sustained, fat-mass-driven improvements in body composition and whether changes in eating behavior mediated these effects.

研究概览

地位

完全的

详细说明

Background: continuous glucose monitoring (CGM) technology is expanding from diabetes care to weight management in healthy populations. Individualized glycemic response-guided dietary management may improve weight loss efficiency, but whether a brief 4-week intervention produces sustained body composition benefits remains unclear.

Design: This is a retrospective analysis of data collected in a two-arm, parallel-group randomized controlled trial conducted at He University, Shenyang, China. No new intervention was administered and no new measurements were performed in the present study; all data were retrospectively extracted from existing archived records. Participants were classified into two cohorts according to the exposure documented in the archived data of the parent trial. The archived records document that 60 overweight or obese university students (aged 18-25 years) had been randomized 1:1 by a random number table in the parent trial, and that both groups had worn the GX-01S continuous glucose monitoring system for 4 weeks (28 days). The archived records show that the exposed group had received an individualized glycemic response-guided dietary intervention: weeks 1-2 served as a dietary behavior observation period (CGM glucose profiles and electronic food diaries), and weeks 3-4 comprised the individualized intervention, including structured CGM reports (glucose trend graphs, traffic-light food lists, individually glucose-sensitive time windows), dietary guidance on meal composition and eating order, and standardized researcher feedback. The archived records show that the non-exposed group had worn CGM without dietary guidance; CGM data were visible during weeks 1-2 and blinded during weeks 3-4.

Assessments: The archived dataset contains body composition measurements recorded with the InBody 120 bioelectrical impedance analyzer at Day 0 (baseline), Day 28 (end of the 4-week period), and Day 90 (follow-up), together with Dutch Eating Behavior Questionnaire (DEBQ) records at the same three timepoints. All values were retrospectively extracted; no additional measurement was performed for this study.

Outcomes: Primary outcomes of the parent study were time above range (TAR) change and body weight change, both derived from the archived records. This analysis focuses on body composition outcomes: weight, body mass index (BMI), percent body fat, body fat mass, skeletal muscle mass, visceral fat level, and segmental body fat across five body compartments, together with exploratory mediation analyses testing whether DEBQ subscale changes (restrained, emotional, and external eating) mediated the intervention effect.

Ethics: The parent study was approved by the Institutional Ethics Committee of He University, and all participants provided written informed consent. For this retrospective analysis of anonymized data, the ethics committee approved a waiver of renewed informed consent.

研究类型

观察性的

注册 (实际的)

59

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Liaoning
      • Shenyang、Liaoning、中国
        • He University, Shenyang, Liaoning, China

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不

取样方法

非概率样本

研究人群

Overweight and obese university students (aged 18-25 years) at He University, Shenyang, Liaoning, China, whose records are contained in the archived dataset of a randomized controlled trial of a 4-week continuous glucose monitoring (CGM)-guided personalized dietary intervention. Participants had a body mass index (BMI) ≥ 24 kg/m² or elevated body fat percentage (≥ 25% in men, ≥ 32% in women) and self-reported at least two unhealthy eating behaviors. Of the 60 participants enrolled in the parent trial (30 per group), 59 were included in this retrospective analysis (30 exposed, 29 non-exposed); one non-exposed participant was excluded for missing primary outcome data. All participants were free of diabetes, prediabetes, and other exclusion conditions defined in the study protocol.

描述

Inclusion Criteria:

  • University students aged 18 to 25 years
  • Body mass index (BMI) ≥ 24.0 kg/m², or body fat percentage ≥ 25% (male) / ≥ 32% (female)
  • Self-reported presence of at least two unhealthy eating behaviors
  • Written informed consent

Exclusion Criteria:• Obesity due to endocrine diseases (e.g., Cushing's syndrome, hypothyroidism, hypothalamic obesity) or genetic syndromes

  • Polycystic ovary syndrome (PCOS)
  • Weight gain or glycemic abnormality induced by medications (e.g., glucocorticoids, antipsychotics, insulin secretagogues)
  • Diagnosed diabetes (type 1 or type 2) or prediabetes (fasting glucose ≥ 6.1 mmol/L or glycated hemoglobin (HbA1c)≥ 5.7%)
  • Diagnosed dyslipidemia with lipid-lowering medication
  • High risk of eating disorders identified by the Eating Disorder Diagnostic Scale (EDDS)
  • Severe psychiatric disorders or psychotropic medication use
  • Pregnancy, lactation, or planned pregnancy within 6 months
  • Allergy to CGM adhesive or hydrogel, or active skin disease affecting sensor wear
  • Professional athletes (high-intensity physical activity ≥ 5 times/week, ≥ 60 min/session)
  • Weight change > 5% of initial body weight within the past 3 months
  • Participation in other commercial or clinical weight-loss programs

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Exposed (n=30)
Participants whose archived records from the parent trial indicate that they had received a 4-week individualized glycemic response-guided dietary intervention based on continuous glucose monitoring (CGM) data: dietary behavior observation during weeks 1-2, followed by structured CGM reports, dietary guidance on meal composition and eating order, and standardized researcher feedback during weeks 3-4.
Non-exposed (n=29)
Participants whose archived records from the parent trial indicate that they had worn the CGM system for 4 weeks without receiving dietary guidance or feedback. CGM data were visible during weeks 1-2 and blinded during weeks 3-4. Participants maintained their usual diet and lifestyle. One of the 30 non-exposed participants enrolled in the parent trial was excluded from this retrospective analysis for missing primary outcome data.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Time above range (TAR)
大体时间:Data recorded at baseline, Day 14, and Day 28
Change in the percentage of time above the target glucose range recorded in the archived CGM dataset. Unit of Measure: Percent of time (%).
Data recorded at baseline, Day 14, and Day 28
Body weight
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in body weight recorded in the archived InBody 120 dataset. Unit of Measure: Kilogram (kg).
Data recorded at Day 0, Day 28, and Day 90

次要结果测量

结果测量
措施说明
大体时间
Body fat mass
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in total body fat mass derived from the archived InBody 120 records. Unit of Measure: Kilogram (kg).
Data recorded at Day 0, Day 28, and Day 90
Body mass index (BMI)
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in body mass index, calculated as body weight in kilograms divided by the square of body height in meters, derived from the archived InBody 120 records. Unit of Measure: Kilogram per square meter (kg/m²).
Data recorded at Day 0, Day 28, and Day 90
Percent body fat
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in body fat percentage, calculated as body fat mass divided by total body weight, derived from the archived InBody 120 records. Unit of Measure: Percent (%).
Data recorded at Day 0, Day 28, and Day 90
Skeletal muscle mass
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in skeletal muscle mass derived from the archived InBody 120 records. Unit of Measure: Kilogram (kg).
Data recorded at Day 0, Day 28, and Day 90
Visceral fat level
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in visceral fat level derived from the archived InBody 120 records. Scale range: minimum 1, maximum 20; higher levels indicate greater visceral adiposity (worse). Unit of Measure: InBody visceral fat level (unitless scale, 1-20).
Data recorded at Day 0, Day 28, and Day 90
Waist circumference
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in waist circumference derived from the archived anthropometric records. Unit of Measure: Centimeter (cm).
Data recorded at Day 0, Day 28, and Day 90
Hip circumference
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in hip circumference derived from the archived anthropometric records. Unit of Measure: Centimeter (cm).
Data recorded at Day 0, Day 28, and Day 90
Waist-hip ratio
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in waist-hip ratio, calculated as waist circumference divided by hip circumference, derived from the archived anthropometric records. Unit of Measure: Ratio (unitless).
Data recorded at Day 0, Day 28, and Day 90
Time in range (TIR)
大体时间:Data recorded from Day 0 to Day 28
Change in the percentage of time within the target glucose range derived from the archived CGM records. Unit of Measure: Percent of time (%).
Data recorded from Day 0 to Day 28
Average glucose (AG)
大体时间:Data recorded from Day 0 to Day 28
Change in average glucose derived from the archived CGM records. Unit of Measure: Millimole per liter (mmol/L).
Data recorded from Day 0 to Day 28
Coefficient of variation (CV)
大体时间:Data recorded from Day 0 to Day 28
Change in the coefficient of variation of glucose derived from the archived CGM records. Unit of Measure: Percent (%).
Data recorded from Day 0 to Day 28
DEBQ restrained eating subscale
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the restrained eating subscale score of the Dutch Eating Behavior Questionnaire (DEBQ), scored as the mean of its item ratings on a scale from 1 (minimum) to 5 (maximum), derived from the archived records. Higher scores indicate a greater tendency toward restrained eating; in this study, increases in this score were considered favorable (better dietary self-regulation). Unit of Measure: Subscale score (1-5).
Data recorded at Day 0, Day 28, and Day 90
DEBQ emotional eating subscale
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the emotional eating subscale score of the Dutch Eating Behavior Questionnaire (DEBQ), scored as the mean of its item ratings on a scale from 1 (minimum) to 5 (maximum), derived from the archived records. Higher scores indicate a greater tendency to eat in response to negative emotions; in this weight-management context, higher scores are considered unfavorable (worse outcome). Unit of Measure: Subscale score (1-5).
Data recorded at Day 0, Day 28, and Day 90
DEBQ external eating subscale
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the external eating subscale score of the Dutch Eating Behavior Questionnaire (DEBQ), scored as the mean of its item ratings on a scale from 1 (minimum) to 5 (maximum), derived from the archived records. Higher scores indicate a greater tendency to eat in response to external food cues; in this weight-management context, higher scores are considered unfavorable (worse outcome). Unit of Measure: Subscale score (1-5).
Data recorded at Day 0, Day 28, and Day 90
Eating Disorder Diagnostic Scale (EDDS) score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the Eating Disorder Diagnostic Scale (EDDS) symptom composite score derived from the archived records. Scale range: minimum 0, maximum 227; higher scores indicate more severe eating disorder symptoms (worse outcome). Unit of Measure: Score (0-227).
Data recorded at Day 0, Day 28, and Day 90
Pittsburgh Sleep Quality Index (PSQI) score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the Pittsburgh Sleep Quality Index (PSQI) global score derived from the archived records. Scale range: minimum 0, maximum 21; higher scores indicate poorer sleep quality (worse outcome). Unit of Measure: Score (0-21).
Data recorded at Day 0, Day 28, and Day 90
Perceived Stress Scale (PSS-10) score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the Perceived Stress Scale (PSS-10) total score derived from the archived records. Scale range: minimum 0, maximum 40; higher scores indicate greater perceived stress (worse outcome). Unit of Measure: Score (0-40).
Data recorded at Day 0, Day 28, and Day 90
Traditional Chinese Medicine (TCM) balanced constitution score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the balanced constitution score of the Constitution in Chinese Medicine Questionnaire (CCMQ), transformed to a 0-100 scale per the standard scoring formula, derived from the archived records. Scale range: minimum 0, maximum 100; higher scores indicate a more balanced constitution (better outcome). Unit of Measure: Score (0-100).
Data recorded at Day 0, Day 28, and Day 90
TCM qi-deficiency constitution score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the qi-deficiency constitution score of the Constitution in Chinese Medicine Questionnaire (CCMQ), transformed to a 0-100 scale per the standard scoring formula, derived from the archived records. Scale range: minimum 0, maximum 100; higher scores indicate stronger expression of this constitution type, i.e., greater constitutional imbalance (worse outcome). Unit of Measure: Score (0-100).
Data recorded at Day 0, Day 28, and Day 90
TCM yang-deficiency constitution score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the yang-deficiency constitution score of the Constitution in Chinese Medicine Questionnaire (CCMQ), transformed to a 0-100 scale per the standard scoring formula, derived from the archived records. Scale range: minimum 0, maximum 100; higher scores indicate stronger expression of this constitution type, i.e., greater constitutional imbalance (worse outcome). Unit of Measure: Score (0-100).
Data recorded at Day 0, Day 28, and Day 90
TCM yin-deficiency constitution score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the yin-deficiency constitution score of the Constitution in Chinese Medicine Questionnaire (CCMQ), transformed to a 0-100 scale per the standard scoring formula, derived from the archived records. Scale range: minimum 0, maximum 100; higher scores indicate stronger expression of this constitution type, i.e., greater constitutional imbalance (worse outcome). Unit of Measure: Score (0-100).
Data recorded at Day 0, Day 28, and Day 90
TCM phlegm-dampness constitution score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the phlegm-dampness constitution score of the Constitution in Chinese Medicine Questionnaire (CCMQ), transformed to a 0-100 scale per the standard scoring formula, derived from the archived records. Scale range: minimum 0, maximum 100; higher scores indicate stronger expression of this constitution type, i.e., greater constitutional imbalance (worse outcome). Unit of Measure: Score (0-100).
Data recorded at Day 0, Day 28, and Day 90
TCM damp-heat constitution score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the damp-heat constitution score of the Constitution in Chinese Medicine Questionnaire (CCMQ), transformed to a 0-100 scale per the standard scoring formula, derived from the archived records. Scale range: minimum 0, maximum 100; higher scores indicate stronger expression of this constitution type, i.e., greater constitutional imbalance (worse outcome). Unit of Measure: Score (0-100).
Data recorded at Day 0, Day 28, and Day 90
TCM blood-stasis constitution score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the blood-stasis constitution score of the Constitution in Chinese Medicine Questionnaire (CCMQ), transformed to a 0-100 scale per the standard scoring formula, derived from the archived records. Scale range: minimum 0, maximum 100; higher scores indicate stronger expression of this constitution type, i.e., greater constitutional imbalance (worse outcome). Unit of Measure: Score (0-100).
Data recorded at Day 0, Day 28, and Day 90
TCM qi-stagnation constitution score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the qi-stagnation constitution score of the Constitution in Chinese Medicine Questionnaire (CCMQ), transformed to a 0-100 scale per the standard scoring formula, derived from the archived records. Scale range: minimum 0, maximum 100; higher scores indicate stronger expression of this constitution type, i.e., greater constitutional imbalance (worse outcome). Unit of Measure: Score (0-100).
Data recorded at Day 0, Day 28, and Day 90
TCM special diathesis constitution score
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in the special diathesis constitution score of the Constitution in Chinese Medicine Questionnaire (CCMQ), transformed to a 0-100 scale per the standard scoring formula, derived from the archived records. Scale range: minimum 0, maximum 100; higher scores indicate stronger expression of this constitution type, i.e., greater constitutional imbalance (worse outcome). Unit of Measure: Score (0-100).
Data recorded at Day 0, Day 28, and Day 90
Right arm fat mass
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in body fat mass of the right arm derived from the archived InBody 120 records. Unit of Measure: Kilogram (kg).
Data recorded at Day 0, Day 28, and Day 90
Left arm fat mass
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in body fat mass of the left arm derived from the archived InBody 120 records. Unit of Measure: Kilogram (kg).
Data recorded at Day 0, Day 28, and Day 90
Trunk fat mass
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in body fat mass of the trunk derived from the archived InBody 120 records. Unit of Measure: Kilogram (kg).
Data recorded at Day 0, Day 28, and Day 90
Right leg fat mass
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in body fat mass of the right leg derived from the archived InBody 120 records. Unit of Measure: Kilogram (kg).
Data recorded at Day 0, Day 28, and Day 90
Left leg fat mass
大体时间:Data recorded at Day 0, Day 28, and Day 90
Change in body fat mass of the left leg derived from the archived InBody 120 records. Unit of Measure: Kilogram (kg).
Data recorded at Day 0, Day 28, and Day 90

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Jun Li, MD、He University, Shenyang, Liaoning, China

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年6月27日

初级完成 (实际的)

2026年7月30日

研究完成 (实际的)

2026年8月15日

研究注册日期

首次提交

2026年8月25日

首先提交符合 QC 标准的

2026年9月8日

首次发布 (实际的)

2026年9月14日

研究记录更新

最后更新发布 (实际的)

2026年9月14日

上次提交的符合 QC 标准的更新

2026年9月8日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅